Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-α: A description of a phase I-II protocol

International Journal of Hyperthermia

Volumn 24, Issue 8, 2008, Pages 649-662

  Bull, Joan M C ^a   Scott, Glenna L ^c   Strebel, Frederick R ^a   Nagle, Verne L ^a   Oliver, Dwight ^b   Redwine, Michael ^a   Rowe, R Wanda ^a   Ahn, Chul W ^c   Koch, Steven M ^c  

^a The University Clinical Research Center   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cisplatin; Fever range whole body thermal therapy (FR WB TT); Gemcitabine; Interferon (IFN ); Optimized timing schedule

Indexed keywords

ALPHA INTERFERON; ANTIEMETIC AGENT; BICALUTAMIDE; CAPECITABINE; CARBOPLATIN; CELECOXIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FENTANYL; FENTANYL CITRATE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; GRANISETRON; IRINOTECAN; LEUPRORELIN; LORAZEPAM; MIDAZOLAM; NAVELBINE; OXALIPLATIN; PACLITAXEL; PARACETAMOL; PROMETHAZINE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; THALIDOMIDE; TOPOTECAN; UNINDEXED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BURN; CANCER CONTROL; CANCER DIAGNOSIS; CANCER PAIN; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSCIOUS SEDATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER RANGE WHOLE BODY THERMAL THERAPY; FLUID THERAPY; GASTROINTESTINAL TOXICITY; HEART FUNCTION; HUMAN; HYDRATION; HYPERTHERMIC THERAPY; INJURY; LABORATORY TEST; LEUKOPENIA; LOW DRUG DOSE; LUNG FUNCTION; MALAISE; MALE; MENTAL DISEASE; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OTOTOXICITY; OUTCOME ASSESSMENT; PAIN; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRESSURE INJURY; QUALITY OF LIFE; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; TEMPERATURE MEASUREMENT; THERAPY DELAY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INTERFERON-ALPHA; KAPLAN-MEIERS ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; QUALITY OF LIFE;

EID: 57649229038     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.1080/02656730802104740     Document Type: Article

References (47)

1. Wondergem, J., Bulger, RE, Strebel, FR, Newman, RA, Travis, EL, Stephens, LC and Bull, JM (1988) Effect of cis-diamminedichloroplatinum(II) combined with whole body hyperthermia on renal injury. Cancer Res, 48, pp. 440-446.
2. Ohno, S., Siddik, ZH, Baba, H., Stephens, LC, Strebel, FR, Wondergem, J., Khokhar, AR and Bull, JM (1991) Effect of carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats. Cancer Res, 51, pp. 2994-3000.
3. Baba, H., Siddik, ZH, Strebel, FR, Jenkins, GN and Bull, JM (1989) Increased therapeutic gain of combined cis-diamminedichloroplatinum(II) and whole body hyperthermia therapy by optimal heat/drug scheduling. Cancer Res, 49, pp. 7041-7044.
4. Bull, J., Loo, C., Strebel, F., Jenkins, G., Tomoda, M. and Rowe, R. (1999) Treatment of a highly metastatic mammary adenocarcinoma with fever-range, long-duration, low temperature (40°C for 6 h) whole body hyperthermia (LL-WBH) combined with gemcitabine (dFdC) in rats. Proceedings of the 90th meeting of the American Association for Cancer Research, p. 3643. Philadelphia, PA
5. Bull, J., Strebel, F., Jenkins, G., Tomoda, M. and Rowe, R. (2000) Sequence-dependency of antitumor effect of gemcitabine combined with cisplatin in the highly metastatic MTLN3 rat mammary adenocarcinoma. Proceedings of the 91st Annual Meeting of the American Association for Cancer Research, p. 410. San Francisco, CA
6. Bull, J., Strebel, F., Rowe, R. and Deng, W. (2008) The importance of schedule in whole-body thermochemotherapy. Int J Hyperthermia, 2, pp. 171-181.
7. Tannir, NM, Cohen, L., Wang, X., Thall, P., Mathew, PF, Jonasch, E., Siefker-Radtke, A., Pagliaro, LC, Ng, CS and Logothetis, C. (2006) Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: Results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer, 107, pp. 2254-2261.
8. Fidler, I. (2001) Regulation of neoplastic angiogenesis. J Natl Cancer Inst Monogr, 28, pp. 10-14.
9. Folkman, J. and Ingber, D. (1992) Inhibition of angiogenesis. Semin Cancer Biol, 3, pp. 89-96.
10. Belardelli, F., Ferrantini, M., Proietti, E. and Kirkwood, JM (2002) Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev, 13, pp. 119-134.
11. Brassard, DL, Grace, MJ and Bordens, RW (2002) Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol, 71, pp. 565-581.
12. Marler, JJ, Rubin, JB, Trede, NS, Connors, S., Grier, H., Upton, J., Mulliken, JB and Folkman, J. (2002) Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: Report of 2 cases. Pediatrics, 109, p. E37.
13. Matsuda, H., Strebel, FR, Kaneko, T., Danhauser, LL, Jenkins, GN, Toyota, N. and Bull, JM (1997) Long duration-mild whole body hyperthermia of up to 12 hours in rats: Feasibility, and efficacy on primary tumour and axillary lymph node metastases of a mammary adenocarcinoma: Implications for adjuvant therapy. Int J Hyperthermia, 13, pp. 89-98.
14. Bull, JMC, Strebel, F., Jenkins, G. and Nagle, V. (1998) A preclinical breast cancer protocol combining fever-range whole-body hyperthermia with Doxil. Proceedings of the 16th Annual San Antonio Conference on Breast Cancer, p. 32. San Antonio, TX
15. Pritchard, MT, Ostberg, JR, Evans, SS, Burd, R., Kraybill, W., Bull, JM and Repasky, EA (2004) Protocols for simulating the thermal component of fever: Preclinical and clinical experience. Methods, 32, pp. 54-62.
16. Schag, CC, Heinrich, RL and Ganz, PA (1984) Karnofsky performance status revisited: Reliability, validity, and guidelines. J Clin Oncol, 2, pp. 187-193.
17. Tuma, RS (2006) Sometimes size doesn't matter: Reevaluating RECIST and tumor response rate endpoints. J Natl Cancer Inst, 98, pp. 1272-1274.
18. Therasse, P., Eisenhauer, EA and Verweij, J. (2006) RECIST revisited: A review of validation studies on tumour assessment. Eur J Cancer, 42, pp. 1031-1039.
19. Folkman, J. (1999) Angiogenesis research: From laboratory to clinic. Forum (Genoa, Italy), 9, pp. 59-62.
20. Goodman, SN, Zahurak, ML and Piantadosi, S. (1995) Some practical improvements in the continual reassessment method for phase I studies. Stat Med, 14, pp. 1149-1161.
21. Ahn, C. (1998) An evaluation of phase I cancer clinical trial designs. Stat Med, 17, pp. 1537-1549.
22. Wolff, RA, Evans, DB, Gravel, DM, Lenzi, R., Pisters, PW, Lee, JE, Janjan, NA, Charnsangavej, C. and Abbruzzese, JL (2001) Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res, 7, pp. 2246-2253.
23. Tempero, M., Plunkett, W., Ruiz Van Haperen, V, Hainsworth, J., Hochster, H., Lenzi, R. and Abbruzzese, J. (2003) Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol, 21, pp. 3402-3408.
24. Storniolo, AM, Allerheiligen, SR and Pearce, HL (1997) Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol, 24, pp. S7-2-7.
25. Grunewald, R., Abbruzzese, JL, Tarassoff, P. and Plunkett, W. (1991) Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer chemotherapy and pharmacology, 27, pp. 258-262.
26. Kraybill, WG, Olenki, T., Evans, SS, Ostberg, JR, O'Leary, KA, Gibbs, JF and Repasky, EA (2002) A phase I study of fever-range whole body hyperthermia (FR-WBH) in patients with advanced solid tumours: Correlation with mouse models. Int J Hyperthermia, 18, pp. 253-266.
27. Trotti, A., Colevas, AD, Setser, A., Rusch, V., Jaques, D., Budach, V., Langer, C., Murphy, B., Cumberlin, R. Coleman, CN et al. (2003) CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol, 13, pp. 176-181.
28. Kaplan, E. and Meier, P. (1958) Nonparametric estimation from incomplete observations. J Amer Stat Assoc, 53, pp. 457-481.
29. Song, CW, Park, H. and Griffin, RJ (2001) Improvement of tumor oxygenation by mild hyperthermia. Radiation research, 155, pp. 515-528.
30. Song, CW, Park, HJ, Lee, CK and Griffin, R. (2005) Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int J Hyperthermia, 21, pp. 761-767.
31. Jain, RK (1989) Delivery of novel therapeutic agents in tumors: Physiological barriers and strategies. J Natl Cancer Inst, 81, pp. 570-576.
32. Boucher, Y., Kirkwood, JM, Opacic, D., Desantis, M. and Jain, RK (1991) Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res, 51, pp. 6691-6694.
33. Jain, RK (1997) The Eugene M. Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors. Microcirculation, 4, pp. 1-23.
34. Sultana, A., Smith, CT, Cunningham, D., Starling, N., Neoptolemos, JP and Ghaneh, P. (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol, 25, pp. 2607-2615.
35. Haddock, MG, Swaminathan, R., Foster, NR, Hauge, MD, Martenson, JA, Camoriano, JK, Stella, PJ, Tenglin, RC, Schaefer, PL Jr Moore, DF et al. (2007) Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: Results of the North Central Cancer Treatment Group Phase II Study N9942. J Clin Oncol, 25, pp. 2567-2572.
36. Ostberg, JR and Repasky, EA (2000) Use of mild, whole body hyperthermia in cancer therapy. Immunol Invest, 29, pp. 139-142.
37. Burd, R., Dziedzic, TS, Xu, Y., Caligiuri, MA, Subjeck, JR and Repasky, EA (1998) Tumor cell apoptosis, lymphocyte recruitment and tumor vascular changes are induced by low temperature, long duration (fever-like) whole body hyperthermia. J Cell Physiol, 177, pp. 137-147.
38. Chen, Q., Fisher, DT, Clancy, KA, Gauguet, JM, Wang, WC, Unger, E., Rose-John, S., von Andrian, UH, Baumann, H. and Evans, SS (2006) Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism. Nature immunology, 7, pp. 1299-1308.
39. Ostberg, JR and Repasky, EA (2006) Emerging evidence indicates that physiologically relevant thermal stress regulates dendritic cell function. Cancer Immunol Immunother, 55, pp. 292-298.
40. Niessner, A., Sato, K., Chaikof, EL, Colmegna, I., Goronzy, JJ and Weyand, CM (2006) Pathogen-sensing plasmacytoid \dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha. Circulation, 114, pp. 2482-2489.
41. Mescher, MF, Curtsinger, JM, Agarwal, P., Casey, KA, Gerner, M., Hammerbeck, CD, Popescu, F. and Xiao, Z. (2006) Signals required for programming effector and memory development by CD8 + T cells. Immunological reviews, 211, pp. 81-92.
42. Slaton, JW, Perrotte, P., Inoue, K., Dinney, CP and Fidler, IJ (1999) Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res, 5, pp. 2726-2734.
43. Pillarisetty, VG, Miller, G., Shah, AB and DeMatteo, RP (2003) GM-CSF expands dendritic cells and their progenitors in mouse liver. Hepatology (Baltimore, Md), 37, pp. 641-652.
44. Pulendran, B., Dillon, S., Joseph, C., Curiel, T., Banchereau, J. and Mohamadzadeh, M. (2004) Dendritic cells generated in the presence of GM-CSF plus IL-15 prime potent CD8 + Tc1 responses in vivo. Eur J Immun, 34, pp. 66-73.
45. Gomez-Cambronero, J. (2003) Rapamycin inhibits GM-CSF-induced neutrophil migration. FEBS letters, 550, pp. 94-100.
46. Shen, L., Smith, JM, Shen, Z., Hussey, SB, Wira, CR and Fanger, MW (2006) Differential regulation of neutrophil chemotaxis to IL-8 and fMLP by GM-CSF: Lack of direct effect of oestradiol. Immunology, 117, pp. 205-212.
47. Davidson, SE, Trotti, A., Ataman, OU, Seong, J., Lau, FN, da Motta, NW and Jeremic, B. (2007) Improving the capture of adverse event data in clinical trials: The role of the international atomic energy agency. Int J Radiat Oncol Biol Phys, 69, pp. 1218-1213.